|
HAYWARD, CA, February 15, 2000 - Sepragen Corporation (OTC BB:
SPGNU, SPGNA, SPGNW) today announced the signing of three new distributors
for its biotech separations products in Europe.
The new distributors are Analis S.A. for
Belgium, Proteigene S. A. for France and Switzerland, and KronLab GmbH for the
German speaking countries (Germany, Austria and Switzerland). Sepragen’s larger European based customers
include Aventis, Baxter International, Glaxo Wellcome, Serono and Smith-Kline
Beecham.
Vinit Saxena, Chairman and CEO of Sepragen
commented, “Our products are increasingly being used in the isolation and
manufacture of ‘new generation’ biological drugs being brought to the market,”
he continued “This increased support will provide our customers greater
security in committing long-term resources towards adopting our unique
technology for their production needs.”
Sepragen Corporation develops and markets technology along with equipment and supplies
for process chromatography applications. Sepragen has developed a number of patented
applications that provide large market opportunities in the food and beverage industry,
including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as
well as extracting proteins from whey. The company holds over 14 issued patents relating
to its core technology.
<
Back
The statements in this release that relate to future events
or performance, statements about growth, future regulatory clearances, levels of sales and
market size and future manufacturing capacity and efficiencies are forward-looking
statements that involve risks and uncertainties, including risks associated with
uncertainties related to the development of markets for and commercial acceptance of the
company's products and services, the availability of components, competitors' product
introductions and other risks identified in the company's SEC filings. Actual results may
differ from those described in these forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the
date hereof.
|
